File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Article: The predictive role of plasma TGF-β1 during radiation therapy for radiation-induced lung toxicity deserves further study in patients with non-small cell lung cancer

TitleThe predictive role of plasma TGF-β1 during radiation therapy for radiation-induced lung toxicity deserves further study in patients with non-small cell lung cancer
Authors
KeywordsLung cancer
Transforming growth factor β1
Radiation-induced lung toxicity
Radiation therapy
Issue Date2008
Citation
Lung Cancer, 2008, v. 59, n. 2, p. 232-239 How to Cite?
AbstractBackground: This study aimed to further investigate the role of circulating TGF-β1 during radiation therapy (RT) in predicting radiation-induced lung toxicity (RILT). Methods and materials: Patients with stages I-III non-small cell lung cancer treated with RT based therapy were included in this study. Platelet poor plasma was obtained pre-RT, at 2 and 4 weeks during-RT, and at the end of RT. TGF-β1 was measured using an enzyme-linked immunosorbent assay. The primary endpoint for RILT was ≥grade 2 radiation pneumonitis or fibrosis. Results: Twenty-six patients with a minimum follow-up of 12 months were included. Six patients (23.1%) experienced ≥grade 2 RILT. There was no significant difference in absolute TGF-β1 levels pre-RT, at 2 and 4 weeks during-RT, or at the end of RT between patients with and without RILT. The TGF-β1 ratios (over the pre-RT levels) for patients with and without RILT at 2, 4 weeks during-, and the end of RT were 2.8 ± 2.2 and 1.0 ± 0.6 (P = 0.123), 2.3 ± 1.3 and 0.8 ± 0.5 (P = 0.001), 1.5 ± 0.9 and 0.8 ± 0.5 (P = 0.098), respectively. Using 2.0 as a cut-off, the TGF-β1 ratio at 4 weeks during-RT predicted RILT with a sensitivity and specificity of 66.7% and 95.0%, respectively. Conclusion: Elevation of plasma TGF-β1 level 4 weeks during-RT is significantly predictive of RILT. The role of plasma TGF-β1 in predicting RILT deserves further study. © 2007 Elsevier Ireland Ltd. All rights reserved.
Persistent Identifierhttp://hdl.handle.net/10722/266877
ISSN
2023 Impact Factor: 4.5
2023 SCImago Journal Rankings: 1.761
ISI Accession Number ID

 

DC FieldValueLanguage
dc.contributor.authorZhao, Lujun-
dc.contributor.authorSheldon, Kerby-
dc.contributor.authorChen, Ming-
dc.contributor.authorYin, Moli S.-
dc.contributor.authorHayman, James A.-
dc.contributor.authorKalemkerian, Gregory P.-
dc.contributor.authorArenberg, Doug-
dc.contributor.authorLyons, Susan E.-
dc.contributor.authorCurtis, Jeffrey L.-
dc.contributor.authorDavis, Mary-
dc.contributor.authorCease, Kemp B.-
dc.contributor.authorBrenner, Dean-
dc.contributor.authorAnscher, Mitchell S.-
dc.contributor.authorLawrence, Theodore S.-
dc.contributor.authorKong, Feng Ming-
dc.date.accessioned2019-01-31T07:19:52Z-
dc.date.available2019-01-31T07:19:52Z-
dc.date.issued2008-
dc.identifier.citationLung Cancer, 2008, v. 59, n. 2, p. 232-239-
dc.identifier.issn0169-5002-
dc.identifier.urihttp://hdl.handle.net/10722/266877-
dc.description.abstractBackground: This study aimed to further investigate the role of circulating TGF-β1 during radiation therapy (RT) in predicting radiation-induced lung toxicity (RILT). Methods and materials: Patients with stages I-III non-small cell lung cancer treated with RT based therapy were included in this study. Platelet poor plasma was obtained pre-RT, at 2 and 4 weeks during-RT, and at the end of RT. TGF-β1 was measured using an enzyme-linked immunosorbent assay. The primary endpoint for RILT was ≥grade 2 radiation pneumonitis or fibrosis. Results: Twenty-six patients with a minimum follow-up of 12 months were included. Six patients (23.1%) experienced ≥grade 2 RILT. There was no significant difference in absolute TGF-β1 levels pre-RT, at 2 and 4 weeks during-RT, or at the end of RT between patients with and without RILT. The TGF-β1 ratios (over the pre-RT levels) for patients with and without RILT at 2, 4 weeks during-, and the end of RT were 2.8 ± 2.2 and 1.0 ± 0.6 (P = 0.123), 2.3 ± 1.3 and 0.8 ± 0.5 (P = 0.001), 1.5 ± 0.9 and 0.8 ± 0.5 (P = 0.098), respectively. Using 2.0 as a cut-off, the TGF-β1 ratio at 4 weeks during-RT predicted RILT with a sensitivity and specificity of 66.7% and 95.0%, respectively. Conclusion: Elevation of plasma TGF-β1 level 4 weeks during-RT is significantly predictive of RILT. The role of plasma TGF-β1 in predicting RILT deserves further study. © 2007 Elsevier Ireland Ltd. All rights reserved.-
dc.languageeng-
dc.relation.ispartofLung Cancer-
dc.subjectLung cancer-
dc.subjectTransforming growth factor β1-
dc.subjectRadiation-induced lung toxicity-
dc.subjectRadiation therapy-
dc.titleThe predictive role of plasma TGF-β1 during radiation therapy for radiation-induced lung toxicity deserves further study in patients with non-small cell lung cancer-
dc.typeArticle-
dc.description.naturelink_to_subscribed_fulltext-
dc.identifier.doi10.1016/j.lungcan.2007.08.010-
dc.identifier.pmid17905467-
dc.identifier.scopuseid_2-s2.0-38649099697-
dc.identifier.volume59-
dc.identifier.issue2-
dc.identifier.spage232-
dc.identifier.epage239-
dc.identifier.isiWOS:000254073500012-
dc.identifier.issnl0169-5002-

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats